volume 5, issue S1, PS22-S24 2016
DOI: 10.21037/tcr.2016.05.12
View full text
|
|
Share

Abstract: Figure 1 Forest plots of hazard ratios for overall survival comparing apatinib to the placebo in third line of treatment in metastatic gastric cancer. The Chi-squared test showed moderate heterogeneity between the trials. The random effects model was used.